Theralase Technologies Inc. (TLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Theralase Technologies Inc. (TLT) has a cash flow conversion efficiency ratio of -0.125x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-244.54K ≈ $-176.90K USD) by net assets (CA$1.95 Million ≈ $1.41 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TLT net asset quality index to measure how much of total assets are equity-financed.
Theralase Technologies Inc. - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Theralase Technologies Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Theralase Technologies Inc. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Theralase Technologies Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theralase Technologies Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Great Computer
TWO:8047
|
0.057x |
|
China Fineblanking Technology Co Ltd
TWO:1586
|
0.013x |
|
Dae Chang
KO:012800
|
-0.035x |
|
SERESCO (ACC.P.DESD.)-16
F:XV7
|
N/A |
|
Gemfields Group Ltd
JSE:GML
|
0.053x |
|
Chemfab Alkalis Limited
NSE:CHEMFAB
|
0.030x |
|
Nice D&B Co. Ltd
KQ:130580
|
0.023x |
|
Multifiling Mitra Indonesia
JK:MFMI
|
0.602x |
Annual Cash Flow Conversion Efficiency for Theralase Technologies Inc. (2001–2025)
The table below shows the annual cash flow conversion efficiency of Theralase Technologies Inc. from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see Theralase Technologies Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$1.78 Million ≈ $1.29 Million |
CA$-3.29 Million ≈ $-2.38 Million |
-1.848x | -14.88% |
| 2024-12-31 | CA$2.07 Million ≈ $1.50 Million |
CA$-3.33 Million ≈ $-2.41 Million |
-1.609x | +24.73% |
| 2023-12-31 | CA$1.91 Million ≈ $1.38 Million |
CA$-4.07 Million ≈ $-2.95 Million |
-2.137x | -28.78% |
| 2022-12-31 | CA$3.09 Million ≈ $2.24 Million |
CA$-5.13 Million ≈ $-3.71 Million |
-1.660x | -108.79% |
| 2021-12-31 | CA$5.07 Million ≈ $3.67 Million |
CA$-4.03 Million ≈ $-2.92 Million |
-0.795x | -63.83% |
| 2020-12-31 | CA$9.16 Million ≈ $6.63 Million |
CA$-4.45 Million ≈ $-3.22 Million |
-0.485x | -2.38% |
| 2019-12-31 | CA$13.86 Million ≈ $10.02 Million |
CA$-6.57 Million ≈ $-4.75 Million |
-0.474x | +61.07% |
| 2018-12-31 | CA$998.64K ≈ $722.40K |
CA$-1.22 Million ≈ $-879.39K |
-1.217x | +41.54% |
| 2017-12-31 | CA$2.05 Million ≈ $1.48 Million |
CA$-4.26 Million ≈ $-3.08 Million |
-2.082x | -142.84% |
| 2016-12-31 | CA$5.69 Million ≈ $4.12 Million |
CA$-4.88 Million ≈ $-3.53 Million |
-0.858x | -7.39% |
| 2015-12-31 | CA$6.32 Million ≈ $4.57 Million |
CA$-5.04 Million ≈ $-3.65 Million |
-0.799x | +27.19% |
| 2014-12-31 | CA$3.31 Million ≈ $2.39 Million |
CA$-3.63 Million ≈ $-2.62 Million |
-1.097x | -111.05% |
| 2013-12-31 | CA$1.76 Million ≈ $1.28 Million |
CA$-916.67K ≈ $-663.11K |
-0.520x | -105.54% |
| 2012-12-31 | CA$-64.73K ≈ $-46.82K |
CA$-606.72K ≈ $-438.89K |
9.373x | +405.21% |
| 2011-12-31 | CA$455.16K ≈ $329.25K |
CA$-1.40 Million ≈ $-1.01 Million |
-3.071x | -663.82% |
| 2010-12-31 | CA$2.53 Million ≈ $1.83 Million |
CA$-1.02 Million ≈ $-735.94K |
-0.402x | -3323.44% |
| 2009-12-31 | CA$3.49 Million ≈ $2.52 Million |
CA$-40.95K ≈ $-29.62K |
-0.012x | +92.02% |
| 2008-12-31 | CA$2.39 Million ≈ $1.73 Million |
CA$-351.19K ≈ $-254.05K |
-0.147x | -41.17% |
| 2007-12-31 | CA$3.37 Million ≈ $2.44 Million |
CA$-351.49K ≈ $-254.26K |
-0.104x | -1262.74% |
| 2006-12-31 | CA$3.37 Million ≈ $2.44 Million |
CA$-25.78K ≈ $-18.65K |
-0.008x | -130.39% |
| 2005-12-31 | CA$3.39 Million ≈ $2.45 Million |
CA$85.33K ≈ $61.73K |
0.025x | +130.40% |
| 2004-12-31 | CA$1.05 Million ≈ $762.12K |
CA$-87.23K ≈ $-63.10K |
-0.083x | +82.82% |
| 2003-12-31 | CA$399.21K ≈ $288.78K |
CA$-192.39K ≈ $-139.17K |
-0.482x | +13.24% |
| 2002-12-31 | CA$87.35K ≈ $63.19K |
CA$-48.52K ≈ $-35.10K |
-0.555x | +7.87% |
| 2001-12-31 | CA$137.03K ≈ $99.13K |
CA$-82.62K ≈ $-59.76K |
-0.603x | -- |
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form … Read more